Abstract

Hepatocellular carcinoma (HCC) samples were clustered into three energy metabolism-related molecular subtypes (C1, C2, and C3) with different prognosis using the gene expression data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). HCC energy metabolism-related molecular subtype analysis was conducted based on the 594 energy metabolism genes. Differential expression analysis yielded 576 differentially expressed genes (DEGs) among the three subtypes, which were closely related to HCC progression. Six genes were finally selected from the 576 DEGs through LASSO-Cox regression and used in constructing a six-gene signature-associated prognostic risk model, which was validated using the TCGA internal and three GEO external validation cohorts. The risk model showed that high ANLN, ENTPD2, TRIP13, PLAC8, and G6PD expression levels were associated with bad prognosis, and high expression of ADH1C was associated with a good prognosis. The validation results showed that our risk model had a high distinguishing ability of prognosis in HCC patients. The four enriched pathways of the risk model were obtained by gene set enrichment analysis (GSEA) and found to be associated with the tumorigenesis and development of HCC, including the cell cycle, Wnt signaling pathway, drug metabolism cytochrome P450, and primary bile acid biosynthesis. The risk score calculated from the established risk model in 204 samples and other clinical characteristics were used in building a nomogram with a good prognostic prediction ability (C-index = 0.746, 95% CI = 0.714–0.777). The area under the curves (AUCs) of the nomogram model in 1-, 2-, and 3-years were 0.82, 0.77, and 0.79, respectively. Then, qRT-PCR and immunohistochemistry were used to validate the mRNA expression levels of the six genes, and significant differences in mRNA and gene expression were observed among the tumor and adjacent tissues. Overall, our study divided HCC patients into three energy metabolism-related molecular subtypes with different prognosis. Then, a risk model with a good performance in prognostic prediction was built using the TCGA dataset. This model can be used as an independent prognostic evaluation index for HCC patients.

Highlights

  • Hepatocellular carcinoma (HCC) is the most common primary liver cancer and has been an important medical problem worldwide

  • The The Cancer Genome Atlas (TCGA)-LIHC dataset was randomly divided into two cohorts: training cohort (n = 204) and internal validation dataset (n = 138), and the three Gene Expression Omnibus (GEO) datasets were regarded as the external validation cohorts

  • We found three independent subtypes of metabolism patterns in HCC, but there was no significant difference in the prognosis between C1 and C3 subtypes

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and has been an important medical problem worldwide. HCC is the sixth most common malignancy in the world and the fourth leading cause of cancer-related death. HCC has been identified as the leading cause of death in patients with cirrhosis, and its incidence is expected to increase in the future [1]. Many studies have explored the molecular, cellular, and environmental mechanisms that contribute to the occurrence of HCC, limited options are presently available for clinicians in delaying tumor progression and prolonging patients’ life expectancy. The high recurrence rate and invasiveness of HCC severely limit the improvement of the curative effect of HCC, and the main mechanism of this feature is not fully understood [2]. An effective prediction model is needed for the accurate assessment of the patient’s prognosis

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call